Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: Mirati - What They Never Told You

3 Growth Pharma Stocks to Guard Your Portfolio

The pharma industry is experiencing significant growth, fueled by rising demand for personalized medicines, a revolutionary wave of drug development and robust government support. Therefore, it could be wise to consider fundamentally strong pharma stocks Zoetis (ZTS), Bristol-Myers Squibb (BMY), and Teva Pharmaceutical Industries (TEVA) to guard your portfolio. Read…

StockNews.com · Feb 6, 2024

Billionaire whose family trust owns Spurs denies insider trading – reports

Billionaire whose family trust owns Spurs denies insider trading – reports

Joe Lewis, 86, pleaded not guilty to 16 counts of securities fraud and three charges of conspiracy when he appeared at Manhattan District Court.

The Independent UK · Jul 26, 2023

What is Tottenham Hotspur billionaire Joe Lewis accused of?

What is Tottenham Hotspur billionaire Joe Lewis accused of?

Joe Lewis has been accused of 16 counts of securities fraud in the US. We examine the allegations through the companies he invested in

The Guardian - UK · Jul 26, 2023

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Tottenham owner Joe Lewis to appear in court on insider trading charges

The 86-year-old has been charged with 16 counts of securities fraud and three counts of conspiracy.

The Independent UK · Jul 26, 2023

Tottenham Hotspur owner Joe Lewis charged with ‘brazen’ insider trading

Billionaire allegedly gave friends, employees and romantic partners information on companies in which he was investor

The Guardian - US · Jul 26, 2023

U.S. FDA approves Mirati's lung cancer drug

The U.S. Food and Drug Administration approved Mirati Therapeutics Inc's lung cancer drug adagrasib, the company said on Monday, sending its shares up more than 8% in extended trading.

Reuters · Dec 12, 2022

Mirati Therapeutics Posts 41% Objective Response Rate In Pretreated GI Cancer Patients

Mirati Therapeutics Inc (NASDAQ: MRTX) has announced

Benzinga · Jan 21, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

1

Coverage From

People

Damian Williams

Patrick OConnor

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Medical Pharmaceuticals

Teva Pharmaceutical Industries Limited

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

420,090 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play